Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Gain on bargain purchase (Details)

v3.24.2.u1
Business combinations - Gain on bargain purchase (Details)
3 Months Ended 6 Months Ended
Jun. 01, 2023
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
May 31, 2023
$ / shares
Mar. 06, 2023
$ / shares
Business Acquisition [Line Items]            
Gain on bargain purchase     $ 22,155,000 $ 22,155,000    
TCR2 Therapeutics            
Business Acquisition [Line Items]            
Purchase consideration $ (61,726,000)          
Net assets acquired and liabilities assumed 83,775,000          
Gain on bargain purchase $ 22,049,000     $ 22,000,000    
Remeasurement on bargain purchase   $ 106,000        
Ratio for issuance of Company's ADSs for each TCR2 stock acquired           1.5117
Closing price of Company's ADS | $ / shares         $ 1.02 $ 1.32